-
My Account
In App
My Account
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 62 | 1418.10 | 1419.95 | 7 |
| 3 | 1417.45 | 1422.95 | 3 |
| 6 | 1417.35 | 1423.20 | 101 |
| 97 | 1416.10 | 1423.95 | 5 |
| 97 | 1415.90 | 1424.50 | 160 |
| 0 | Total | Total | 0 |
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 62 | 1418.10 | 1419.95 | 7 |
| 3 | 1417.45 | 1422.95 | 3 |
| 6 | 1417.35 | 1423.20 | 101 |
| 97 | 1416.10 | 1423.95 | 5 |
| 97 | 1415.90 | 1424.50 | 160 |
| 0 | Total | Total | 0 |
| Open | 1,438.00 |
| Previous Close | 1,446.20 |
| Volume | 449,860.00 |
| Value (Lacs) | 6,401.06 |
| VWAP | 0.00 |
| Beta | |
| Mkt Cap (Rs. Cr.) | 23,121 |
| High | 1,443.80 |
| Low | 1,411.60 |
| UC Limit | 0.00 |
| LC Limit | 0.00 |
| 52 Week High | 1,868.80 |
| 52 Week Low | 1,110.05 |
| Face Value | 5.00 |
| All Time High | 1,999.27 |
| All Time Low | 61.30 |
| 20D Avg Volume | 1,188,588 |
| 20D Avg Delivery(%) | 20.98 |
| Book Value Per Share | 281.07 |
| Dividend Yield | 0.00 |
| TTM EPS See historical trend | -1.42 |
| TTM PE See historical trend | -- (Low PE) |
| P/B See historical trend | 5.06 (Average P/B) |
| Sector PE | 39.65 |
*Delayed by 20 seconds.
Stock Score
Get detailed analysis with Moneycontrol Stock Insights.
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| Days | |
|---|---|
| 5 | - - |
| 10 | - - |
| 20 | - - |
| 50 | - - |
| 100 | - - |
| 200 | - - |
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| Days |
|---|
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| Days |
|---|
| 1 Week | --% | |
| 1 Month | --% | |
| 3 Months | --% | |
| YTD | --% | |
| 1 Year | --% | |
| 3 Years | --% |
9 out of 16 years Wockhardt has given negative returns in January.
| Month | Max. Positive Change(%) | Avg. Positive Change(%) | Max. Negative Change(%) | Avg. Negative Change(%) | Average Change(%) |
|---|---|---|---|---|---|
| January | 50.96% (2020) | 21.37% | -16.70% (2016) | -9.47% | 2.69% |
Pharma stocks jump up to 5% after US Senate passes Biosecure Act: Check top gainers Dec 19 2025 01:48 PM
Wockhardtu2019s Zaynich NDA gets USFDA acceptance: What Indiau2019s first NCE means for the company Dec 02 2025 01:59 PM
Wockhardt shares jump 6%, extend gain to 27% in two days after US FDA accepts new drug application for Zaynich Dec 02 2025 11:46 AM
u201cVery confident of positive outcomeu201d: Habil Khorakiwala on USFDA acceptance of Wockhardtu2019s NDA for its novel antibiotic Dec 01 2025 06:56 PM
rkg maverick if they out licence for Europe at 1 to 1 and half billion dollar or ur estimate with 15 to 20 percent profit sharing considering the patent upto 2037 then what is scenario can u help the forum for better understanding View more
Posted by : kani21
Wockhardt is valued at 23k crore, yet a conservative take on Zaynich Europe alone 400 million euros revenue, 40pct margins, and a modest 25x PE puts its value at 36K crore INR. this ignores the US, India, and the rest of the pipeline entirely, making the current valuation look like clear value for-money. View more
Posted by : rkg14
Repost this message
Wockhardt is valued at 23k crore, yet a conservative take on Zaynich Europe alone 400 million euros revenue, 40pct margins, and a modest 25x PE puts its value at 36K crore INR. this ignores the US, India, and the rest of the pipeline entirely, making the current valuation look like clear value for-money.
Posted by : The Fixed Income
Repost this message
A new Senior Secured Bond Opportunity is opening soon. Earn fixed returns of up to 8.90% with the Adani Enterprises Bond Public Issue, opening on 6th January 2026. Rated AA- (Stable) by CARE & ICRA, this senior secured bond offers stability with a minimum investment of just ₹10,000. Pre-book now and lock in predictable income from a high-quality issuer : https://www.thefixedincome.com/product/IPO-details/dXhhdQ-tfi/adani-enterprises-limited?utm_source=Moneycontrol&utm_medium=MCForum&utm_campaign=product_list
*Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.
*A bulk deal is a trade where total quantity of shares bought or sold is more than 0.5% of the equity shares of a company listed on the exchange.
| Date | Agenda |
|---|
| Ex-Date | Type | Dividend (Rs) |
|---|
| Announcement Date | Ex-Bonus | Ratio |
|---|
| Ex-Split | Old FV | New FV |
|---|
| Ex-Right | Ratio | Premium |
|---|
| Date | Agenda |
|---|
Sharpest Opinions & Actionable Insights 
Exclusive Webinars 
Research & Expert Technical Analysis 
